MorphoSys AG (WBO:MOR) Gross Profit : €179.9 Mil (TTM As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is MorphoSys AG Gross Profit?

MorphoSys AG's gross profit for the three months ended in Dec. 2023 was €44.4 Mil. MorphoSys AG's gross profit for the trailing twelve months (TTM) ended in Dec. 2023 was €179.9 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. MorphoSys AG's gross profit for the three months ended in Dec. 2023 was €44.4 Mil. MorphoSys AG's Revenue for the three months ended in Dec. 2023 was €59.1 Mil. Therefore, MorphoSys AG's Gross Margin % for the quarter that ended in Dec. 2023 was 75.20%.

MorphoSys AG had a gross margin of 75.20% for the quarter that ended in Dec. 2023 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of MorphoSys AG was 97.65%. The lowest was 75.48%. And the median was 82.85%.

Warning Sign:

MorphoSys AG gross margin has been in long-term decline. The average rate of decline per year is -4.1%.

MorphoSys AG Gross Profit Historical Data

The historical data trend for MorphoSys AG's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MorphoSys AG Gross Profit Chart

MorphoSys AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross Profit

Get a 7-Day Free Trial

59.67

318.52

147.42

229.65

179.92

MorphoSys AG Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Gross Profit	Get a 7-Day Free Trial															66.15	41.33	45.46	48.70	44.42

Competitive Comparison of MorphoSys AG's Gross Profit

For the Biotechnology subindustry, MorphoSys AG's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MorphoSys AG's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MorphoSys AG's Gross Profit distribution charts can be found below:

* The bar in red indicates where MorphoSys AG's Gross Profit falls into.

MorphoSys AG Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

MorphoSys AG's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )	=	Revenue	-	Cost of Goods Sold
	=	238.278	-	58.354
	=	179.9

MorphoSys AG's Gross Profit for the quarter that ended in Dec. 2023 is calculated as

Gross Profit (Q: Dec. 2023 )	=	Revenue	-	Cost of Goods Sold
	=	59.078	-	14.654
	=	44.4

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €179.9 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

MorphoSys AG's Gross Margin % for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )	=	Gross Profit (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	44.4	/	59.078
	=	75.20 %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

MorphoSys AG (WBO:MOR) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

MorphoSys AG had a gross margin of 75.20% for the quarter that ended in Dec. 2023 => Durable competitive advantage

MorphoSys AG Gross Profit Related Terms

Thank you for viewing the detailed overview of MorphoSys AG's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.

MorphoSys AG (WBO:MOR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MorphoSys AG (WBO:MOR) » Definitions » Gross Profit

Comparable Companies

Traded in Other Exchanges

MPSYF:USA MOR:USA 1MOR:Italy MORd:UK 0NDV:UK MOR:Germany

Address

Semmelweisstrasse 7, Planegg, BY, DEU, 82152

Website

https://www.morphosys.com

MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.